Cell therapy compositions and methods for treating vascular disorders

文档序号：1422056 发布日期：2020-03-17 浏览：26次中文

阅读说明：本技术 细胞治疗组合物及治疗血管病变的方法 (Cell therapy compositions and methods for treating vascular disorders ) 是由肖海蓉刘冰汤乐于 2019-11-23 设计创作，主要内容包括：本发明涉及细胞治疗组合物及治疗血管病变的方法。具体的,本发明涉及一种以脐血造血干细胞为起始材料来制备CD34+细胞的方法,还涉及以该种细胞制备得到的细胞治疗组合物,本发明的细胞治疗组合物可以用于缓解或改善血管病变,例如肢体动脉狭窄闭塞或糖尿病引起的外周动脉病变；尤其是肢体动脉狭窄闭塞或糖尿病引起的下肢动脉病变。所述细胞治疗组合物包含：CD34+细胞、氯化钠、注射用水。还涉及制备细胞治疗组合物的方法,包括如下步骤：将氯化钠加入水中溶解,任选地对该溶液进行除菌,获得制剂的基质；将预先制得的CD34+细胞混悬于该基质中,分装,即得。本发明方法呈现如说明书所述优异技术效果。(The present invention relates to cell therapy compositions and methods of treating vascular disorders. In particular to a method for preparing CD34 by using cord blood hematopoietic stem cells as starting materials + The cell therapy composition can be used for alleviating or improving vascular diseases, such as peripheral arterial diseases caused by limb arterial stenosis occlusion or diabetes; especially due to arterial stenosis of limbs or diabetesLower limb artery disease. The cell therapy composition comprises: CD34 + Cells, sodium chloride, water for injection. Also relates to a method for preparing a cell therapy composition comprising the steps of: dissolving sodium chloride in water, optionally sterilizing the solution to obtain matrix of the preparation; mixing the pre-made CD34 + Suspending the cells in the matrix, and packaging. The method of the present invention exhibits excellent technical effects as described in the specification.)

1. A cell therapy composition comprising: CD34⁺Cells, sodium chloride, water for injection.

2. The cell therapy composition according to claim 1, said CD34⁺The cells are cord blood hematopoietic stem cell source CD34⁺A cell.

3. The cytotherapeutic composition according to claim 1, characterized in that:

CD34⁺the density of cells was 1X 10⁶one/mL to 5X 10⁶one/mL, e.g. 2X 10⁶one/mL to 4X 10⁶one/mL, e.g. 3X 10⁶Per mL;

the mass volume percentage of the sodium chloride is 0.8-1.0% or 0.9%;

the amount of water for injection is added to CD34⁺The amount of cells that reach their specified density;

which comprises the following steps: 1X 10⁶one/mL to 5X 10⁶CD34 of one/mL⁺Cells, 0.8-1.0% of sodium chloride and water for injection;

which comprises the following steps: 2X 10⁶one/mL to 4X 10⁶CD34 of one/mL⁺Cells, 0.8-1.0% of sodium chloride and water for injection;

which comprises the following steps: 3X 10⁶CD34 of one/mL⁺Cells, 0.9% sodium chloride, and water for injection.

4. The cytotherapeutic composition according to claim 1, characterized in that:

wherein the composition further comprises magnesium chloride;

the mass volume percentage of the magnesium chloride is 0.05-0.1%;

the mass volume percentage of the magnesium chloride is 0.08%;

wherein the composition also comprises calcium sodium ethylene diamine tetraacetate;

the mass volume percentage of the ethylene diamine tetraacetic acid calcium sodium is 0.06% -0.08%;

the mass volume percentage of the ethylenediaminetetraacetic acid calcium sodium salt is 0.07%.

5. The cytotherapeutic composition according to claim 1, characterized in that:

(1) which comprises the following steps: CD34⁺Cells 3X 10⁶Sodium chloride 0.9%, magnesium chloride 0.08%, calcium sodium ethylene diamine tetraacetate 0.07%, and water for injection; alternatively, the first and second electrodes may be,

(2) which comprises the following steps: CD34⁺Cell 1X 10⁶Sodium chloride 0.8%, magnesium chloride 0.1%, calcium disodium edetate 0.08%, and water for injection; alternatively, the first and second electrodes may be,

(3) which comprises the following steps: CD34⁺Cell 5X 10⁶Sodium chloride 1.0%, magnesium chloride 0.05%, calcium disodium edetate 0.06%, and water for injection; alternatively, the first and second electrodes may be,

(4) which comprises the following steps: CD34⁺Cells 4X 10⁶Sodium chloride 0.85%, magnesium chloride 0.07%, calcium disodium edetate 0.075%, and water for injection; alternatively, the first and second electrodes may be,

the preparation method comprises the following steps:

dissolving sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium edetate) in water, optionally sterilizing the solution to obtain matrix of the preparation;

mixing the pre-made CD34⁺Suspending the cells in the matrix, and packaging.

6. The cytotherapeutic composition according to claim 1, characterized in that:

the preparation process is carried out under aseptic condition;

during the preparation process, the compound is mixed with CD34⁺The temperature of the matrix prior to cell mixing is less than 25 ℃;

the preparation method comprises mixing the matrix with CD34 at a temperature below 25 deg.C⁺Mixing the cells;

the subpackaging is to subpackage the prepared cell therapy composition into a pre-filled syringe, in particular to a disposable pre-filled syringe;

the material of the syringe of the prefilled syringe is high molecular polymer (such as polypropylene), and the material of the piston is rubber.

7. The cell therapy composition according to claim 1, wherein CD34⁺The cell is prepared by a method comprising the following steps:

(1) isolation of cord blood hematopoietic stem cells: after the collection of fresh umbilical cord blood is finished, separating umbilical cord blood hematopoietic stem cells to obtain nucleated cells;

(2) transferring 5ml of the cord blood hematopoietic stem cells obtained in the step (1) into a 50ml sterile centrifuge tube by using a disposable sterile syringe; adding sterile PBS buffer solution (pH7.2) with the same volume by a dropping method, centrifuging at 1200rpm for 5min, removing the supernatant, adding 40ml sterile PBS buffer solution (pH7.2) again, centrifuging at 1200rpm for 5min, removing the supernatant, and then re-suspending the cell precipitate with PBS buffer solution (pH7.2) with 15-20 times of volume;

(3) separating a Ficoll separation liquid: adding 25ml of Ficoll separating medium into a 50ml sterile centrifuge tube, slowly adding 15ml of cell suspension along the tube wall, centrifuging, sucking the white membrane layer mononuclear cells after centrifugal separation, cleaning for 2 times by using PBS (pH7.2), discarding the supernatant, and fixing the volume to 5ml by using PBS (pH7.2);

(4) CD34 using a flow cytometer (e.g., FC500 type flow cytometer)⁺Cells (i.e., cells positive for the surface marker CD 34) were counted and then read according to CD34⁺The detection result is diluted to CD34 by using a hematopoietic stem cell culture system⁺The cell concentration is 5 x10 ^4 cells/ml; seeding the diluted cells into low-attachment coated 6-well plates at a density of 1 x10 ^5 CD34⁺Cells/well (2ml), then placed in 5% CO2, 37 ℃ incubator for culture;

(5) changing the culture medium on 2, 4 and 6 days of culture, and performing single-well liquid change according to the following operation: transferring the cells into a 15ml sterile centrifuge tube, centrifuging for 5 minutes at 300g, discarding the supernatant, resuspending with a 2ml hematopoietic stem cell culture system, inoculating 2ml suspension into a 6-well plate, and culturing at 37 ℃ under the conditions of 5% CO 2;

(6) day 4 of culture, CD34 was performed⁺Cell counts, when reaching 4-6 x10 ^5 cells according to 1 x10 ^5 CD34⁺Performing plate separation treatment when cells/holes are processed;

(7) day 6 of culture according to CD34⁺Cell counting condition, determining whether plate separation treatment is carried out; if 4-6 x10 ^5 CD34 are reached⁺The cells were plated and cultured for 3 days before harvesting CD34⁺Cells, if less than 4 x10 ^5 CD34⁺The cells were not plated and harvested on the next day (i.e., day 7 of culture) for CD34⁺A cell.

8. The cytotherapeutic composition according to claim 1, characterized in that:

in the step (1), the cord blood hematopoietic stem cells are separated by adopting an AXP full-automatic separation system;

in the step (1), the cord blood hematopoietic stem cells are separated by an AXP full-automatic separation system, and the AXP full-automatic separation system is AXP Auto Xpress^TMPlatform；

In the step (1), the erythrocyte removing rate of the cord blood sample treated by the AXP is usually more than 80%;

the PBS buffer solution is a sodium phosphate salt buffer solution, wherein the concentration of phosphate is 0.025M, and the pH value is 7.2;

in the step (3), the conditions of the centrifugal treatment are as follows: centrifuging at 1800rpm for 20 min;

the hematopoietic stem cell culture system comprises the following components: 25-75 mu g/ml of Human low-density lipoprotein (Human LDL), 5-15 ng/ml of Erythropoietin (EPO), 500-1500 IU/ml of interleukin 3(IL-3), 25-75 ng/ml of Stem Cell Factor (SCF) and a proper amount of animal component-free culture medium (StemBan-ACF) are added to the whole volume of the preparation solution;

the hematopoietic stem cell culture system comprises the following components: human low density lipoprotein (Human LDL)50 mug/ml, Erythropoietin (EPO)10ng/ml, interleukin 3(IL-3)1000IU/ml, Stem Cell Factor (SCF)50ng/ml, animal component free medium (StemBan-ACF) are added in proper amount to the full volume of the solution;

in the step (1), the cord blood hematopoietic stem cells obtained by separation are optionally subjected to cryopreservation and resuscitation treatment and then are used for the treatment in the step (2);

the hematopoietic stem cell culture system also comprises 0.02-0.05 mu mol/L of disodium adipate and 0.05-0.15% (w/v) of maltose.

9. Use of a cytotherapeutic composition of any one of claims 1 to 8 in the manufacture of a medicament for ameliorating or ameliorating a vascular disorder; for example, the disease such as a vascular disease becomes a stenotic occlusion of an artery of a limb or a peripheral arterial disease caused by diabetes; preferably arterial stenosis of the limb or arterial lesions of the lower limb caused by diabetes.

10. A method of preparing a cell therapy composition according to any one of claims 1 to 8, comprising the steps of:

dissolving sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium edetate) in water, optionally sterilizing the solution to obtain matrix of the preparation;

mixing the pre-made CD34⁺Suspending the cells in the matrix, and packaging;

further, it is characterized in that:

the preparation process is carried out under aseptic condition;

during the preparation process, the compound is mixed with CD34⁺The temperature of the matrix prior to cell mixing is less than 25 ℃;

the preparation method comprises mixing the matrix with CD34 at a temperature below 25 deg.C⁺Mixing the cells;

wherein the dispensing is dispensing the formulated cell therapy composition into pre-filled syringes, particularly into single-use pre-filled syringes;

wherein the material of the syringe of the prefilled syringe is high molecular polymer (such as polypropylene), and the material of the piston is rubber.

Technical Field

The invention belongs to the field of biological medicine, and particularly relates to the field of treating clinical diseases by adopting a cell biology technology. In particular to a method for preparing CD34 by using cord blood hematopoietic stem cells as starting materials⁺Methods of using the cells, and to cells so producedThe cell therapy composition prepared by the cells can be used for relieving or improving vascular diseases, such as peripheral arterial diseases caused by limb arterial stenosis occlusion or diabetes; especially the artery occlusion of limbs or the artery pathological changes of lower limbs caused by diabetes.

Background

Stem cells mediate the transfer of regenerative and genetic information to subsequent cell generations. They can self-renew and produce differentiated offspring. In recent years, progress has been made in our understanding of the molecular mechanisms behind the interaction between stem cells and their tissue micro-ecoenvironments. This has led to a better understanding of the molecular regulatory mechanisms that play a role in stem cells.

While gene therapy remains an experimental approach, this technique holds promise for significant impact on human health. Over the past few years, the scope and definition of gene therapy has changed and expanded. In addition to the correction of inherited genetic disorders such as cystic fibrosis, hemophilia and other diseases, gene therapy has also been developed against acquired diseases such as cancer, AIDS, chronic vascular ischemia, osteoarthritis, diabetes, parkinson's disease and alzheimer's disease.

At present, germline gene therapy is not involved due to its complex technical nature and ethical considerations. However, somatic gene therapy that is beneficial to only a single individual (and is not passable) is the primary focus of stem cell research. The first apparently successful clinical trial from the initial description of successful gene transfer into murine hematopoietic stem cells to patients with both x-linked combined immunodeficiency (SCID) and adenosine deaminase deficiency (ADA) -deficiency took more than 15 years. Many aspects of stem cell therapy are under investigation. For example, retroviral vectors have been used in many cases to transfer genes into stem cells to repair mutated or imperfect genes. Such conditions include severe combined immunodeficiency, fanconi anemia, and other hemoglobinopathies.

A central issue in stem cell engineering is the special methodology used to introduce therapeutic genes into progenitor cells. Because retroviruses tend to insert active genes (it is believed that condensed chromatin is open in these regions), it has been proposed that their use may also increase the risk of cancer, as retroviral vectors inserted near genes involved in cell proliferation could theoretically generate precursor cancer stem cells. However, the overall risk of this type of event is difficult to determine. There are many examples of complete success in Chronic Granulomatous Disease (CGD) patients in which NADPH oxidase activity is restored after infusion of genetically altered blood stem cells.

The minimum requirement for productive gene therapy is the sustained production of therapeutic gene products in the correct biological context with minimal deleterious side effects. To achieve this, the use of stem cells in gene therapy would require the development of new strategies for modulating the expression of therapeutic genes and methods for the efficient delivery of exogenous genes to stem cells. Selective control of therapeutic gene expression by differentiating stem cells in a defined tissue environment is an important goal of stem cell engineering. The methods can, for example, help control the differentiation of stem cells into specific lineages, maintain their undifferentiated state for later transplantation, proliferation, and regulate the expression of therapeutic genes such as suicide genes, cytokines, or growth factors in defined tissue environments.

Mesenchymal stem cells are derived from mesoderm and ectoderm in early development, have the characteristics of multidirectional differentiation potential, immunoregulation, self-replication and the like, and are increasingly concerned by people. Under the specific induction condition in vivo or in vitro, the mesenchymal stem cells can be differentiated into various tissue cells such as fat, bone, cartilage, muscle, tendon, ligament, nerve, liver, cardiac muscle, endothelium and the like, still have multidirectional differentiation potential after continuous subculture and cryopreservation, can be used as ideal seed cells for repairing tissue and organ injuries caused by aging and pathological changes, and particularly have great clinical application value for treating the aging and repairing the tissue and organ injuries.

MSC is abundant in bone marrow, but with aging, the number of stem cells in bone marrow is also significantly reduced, and the proliferation and differentiation capacity is also greatly reduced. In addition, the transplantation of bone marrow MSC to foreign body may cause immune reaction, and the damage to the patient during the process of extracting stem cells and other problems encountered during collection directly influence the clinical application of bone marrow MSC, so that the search of other alternative mesenchymal stem cell sources except for bone marrow becomes an important problem.

Recent studies have shown that cord tissue and cord blood also contain mesenchymal stem cells and can be successfully isolated, with cord blood-derived stem cells commonly referred to as hematopoietic stem cells. The mesenchymal stem cells from the source not only keep the biological characteristics of the mesenchymal stem cells, but also have more primitive isolated stem cells and stronger proliferation and differentiation capacities. The functional activity of immune cells is low, and the risk of triggering immune response and causing graft-versus-host disease is greatly reduced. The probability of infection and transmission of latent viruses and microorganisms is low. The collecting process is simple, and has no harm or injury to parturient and newborn. The above reasons are enough to make umbilical cord mesenchymal stem cells an ideal substitute for bone marrow mesenchymal stem cells.

Peripheral Arterial Disease (PAD), especially lower limb arterial disease, is often caused by stenotic occlusion of arterial limbs and diabetes due to arteriosclerotic occlusion and thromboangiitis obliterans. PAD is primarily manifested as severe limb ischemia, especially lower limb ischemia.

At present, clinically, patients with unobstructed distal outflow tracts are often treated by interventional stents and surgical operations. PAD patients often manifest in two cases:

early stage of luminal stenosis: intermittent claudication, characterized by pain that occurs while walking, is mainly manifested;

with the exacerbation of stenosis, there can be a pain of rest, even loss of walking ability and Critical Limb Ischemia (CLI) characterized by the occurrence of tissue necrosis and ulceration.

The prognosis for CLI is very poor, with 5-year survival rates of only 50% or less. Treatment of CLI not only alleviates symptoms, improves function of affected limbs and prevents amputation, but also prevents the progression of systemic Atherosclerosis (AS) to prevent cardiovascular and cerebrovascular events from occurring. The main treatment means at present are: controlling hyperglycemia, hypertension and dyslipidemia; removing risk factors, such as smoking; forced exercise; antiplatelet agents and vasodilator agents; and circulatory reconstructive surgery, such as surgery (e.g., bypass grafting or endarterectomy), endovascular intervention techniques (e.g., stenting or balloon dilation).

After the above treatment, about 40% of CLI patients still do not improve prognosis. For this segment of patients, amputation is currently considered the last treatment option to be made to save lives. But the total mortality rate after amputation is about 25% -50%; the death rate in the perioperative period of amputation is 5% -20%; the secondary amputation rate is approximately 30%. To date, the therapeutic options for CLI remain limited, with approximately 40% of patients not being eligible for, or having, a beneficial response. For these "no other treatment options" patients, drug treatment has very limited effect on slowing disease progression and preventing amputation.

Therefore, exploring new treatment strategies for the revascularization of ischemic limbs is of great clinical importance to reduce amputation and improve quality of life of patients. This has prompted researchers to focus their research on the search for stem cell transplantation with differentiation potential for PAD, who wish to be able to induce stem cells into vascular epithelial cells in the lesion to repair damaged vessels.

Basic research has found that the stem cell types capable of differentiating into vascular endothelial cells include Endothelial Progenitor Cells (EPCs), bone marrow mononuclear cells (BMMNC), and peripheral blood mononuclear cells (PBMNC). However, these stem cells are limited in tissue origin and have limited numbers of extracts and amplifications. Such therapies are currently in preclinical research.

Experiments have proved that human CD34⁺Cells (CD34 is a marker of mature blood vessels) can alleviate the symptoms of CLI, improve the function of affected limbs, and prevent amputation. However, since the content of Wharton's jelly in Wharton's jelly is only about 5% to 10%, how to efficiently produce the cells becomesIs an important prerequisite for obtaining wide application.

To date, CD34 in cord blood⁺The cells are usually isolated by Ficoll separation, hydroxyethyl starch separation and natural sedimentation of gelatin, and the CD34 obtained is subsequently further purified by immunomagnetic bead adsorption (MACS)⁺Cells to obtain satisfactory CD34⁺A cell. The method can directly separate and purify primary CD34 from human umbilical cord blood⁺Cells, CD34 obtainable by the above method in view of limited supply of human cord blood⁺The number of cells is also extremely limited.

2016110569840(Y16070) by the present inventor discloses a method for preparing CD34 positive cells from cord blood hematopoietic stem cells, however, the composition comprising CD34 positive cells described therein is not suitable for storage and transportation over a long period of time, and it has been found that such a composition has a significant decrease in cell viability rate after freezing and thawing, and thus is difficult to be suitable for clinical use, for example, during storage and transportation before clinical use (e.g., during 3 months of cell viability at-80 ℃).

Thus, there remains a need in the art for a method of producing large amounts of CD34 from human cord blood in a relatively simple manner⁺Methods for cell preservation, there is also a need for a composition that can be stored and transported over an extended period of time and that can maintain cell viability after undergoing freezing and thawing.

Disclosure of Invention

The invention aims to provide a method for preparing CD34 from umbilical cord blood⁺Methods for the production of cells and compositions for the preservation of cell viability following freezing and thawing, which compositions are capable of being stored and transported for extended periods of time. It has been surprisingly found that CD34 is prepared using the method of the present invention⁺The cells, as well as the compositions prepared by the methods of the invention, have exhibited superior technical effects such as those described above and below. The present invention has been completed based on this finding.

To this end, the invention provides, in a first aspect, a method for producing CD34 from cord blood hematopoietic stem cells⁺Method for preparing cellsThe method comprises the following steps:

(1) isolation of cord blood hematopoietic stem cells: after the collection of fresh umbilical cord blood is completed, separating umbilical cord blood hematopoietic stem cells to obtain nucleated cells (the invention is also called umbilical cord blood hematopoietic stem cells herein);

(6) day 4 of culture, CD34 was performed⁺Cell counts, when reaching 4-6 x10 ^5 cells according to 1 x10 ^5 CD34⁺Performing plate separation treatment when cells/holes are processed;

(7) day 6 of culture according to CD34⁺Cell counting condition, determining whether plate separation treatment is carried out; if it isUp to 4-6 x10 ^5 CD34⁺The cells were plated and cultured for 3 days before harvesting CD34⁺Cells, if less than 4 x10 ^5 CD34⁺The cells were not plated and harvested on the next day (i.e., day 7 of culture) for CD34⁺A cell;

(8) CD34 using a flow cytometer⁺Count and evaluate CD34⁺Cell expansion effect.

The method according to any one of the embodiments of the first aspect of the present invention, wherein in step (1), the cord blood hematopoietic stem cells are isolated by using an AXP full-automatic isolation system.

The method according to any of the embodiments of the first aspect of the present invention, wherein in the step (1), the cord blood hematopoietic stem cells are separated by using an AXP full-automatic separation system^TMPlatform。

The method according to any one of the embodiments of the first aspect of the present invention, wherein in step (1), the erythrocyte removal rate of the cord blood sample after AXP treatment is usually more than 80%.

The method according to any one of the embodiments of the first aspect of the present invention, wherein the PBS buffer is a sodium phosphate salt buffer, wherein the phosphate concentration is 0.025M, ph 7.2. The sodium phosphate salt buffer may be formulated using sodium dihydrogen phosphate and/or disodium hydrogen phosphate, optionally in combination with phosphoric acid or sodium hydroxide to adjust the pH, such formulation methods being well known to those skilled in the art.

The method according to any one of the embodiments of the first aspect of the present invention, wherein in step (3), the conditions of the centrifugation treatment are: centrifuging at 1800rpm for 20min, increasing speed to 1, and decreasing speed to 0.

The method according to any one of the embodiments of the first aspect of the present invention, wherein the flow cytometer is a FC500 type flow cytometer or other types of flow cytometer commonly used in the art.

The method according to any one of the embodiments of the first aspect of the invention, wherein the composition of the hematopoietic stem cell culture system is: 25-75 μ g/ml of Human low density lipoprotein (Human LDL), 5-15 ng/ml of Erythropoietin (EPO), 500-1500 IU/ml of interleukin 3(IL-3), 25-75 ng/ml of Stem Cell Factor (SCF) and a proper amount of animal component-free culture medium (StemBan-ACF) are added to the whole volume of the preparation solution.

The method according to any one of the embodiments of the first aspect of the invention, wherein the composition of the hematopoietic stem cell culture system is: human low density lipoprotein (Human LDL)50 μ g/ml, Erythropoietin (EPO)10ng/ml, interleukin 3(IL-3)1000IU/ml, Stem Cell Factor (SCF)50ng/ml, animal component free medium (StemBan-ACF) were added in appropriate amounts to the full volume of the formulation.

The method according to any of the embodiments of the first aspect of the present invention, wherein the parameter for evaluating the amplification effect may be, for example, amplification factor, colony forming unit (which may be, for example, CFU-E, BFU-E, CFU-GM, CFU-GEMM, etc.).

The method according to any one of the embodiments of the first aspect of the present invention, wherein in the step (1), the cord blood hematopoietic stem cells obtained by separation are optionally subjected to cryopreservation and resuscitation treatment, and then are used for the treatment of the step (2).

The method according to any one of the embodiments of the first aspect of the present invention, wherein in the step (1), the cord blood hematopoietic stem cells obtained by isolation are subjected to the following cryopreservation treatment: adding cell frozen stock solution into cord blood hematopoietic stem cells obtained by separation, cooling, and storing in a gaseous liquid nitrogen storage tank at-196 ℃.

The method according to any one of the embodiments of the first aspect of the present invention, wherein in step (1), the cryopreserved cord blood hematopoietic stem cells are subjected to resuscitation treatment as follows: taking out the frozen cord blood hematopoietic stem cells from the liquid nitrogen tank, and unfreezing the cord blood hematopoietic stem cells in a water bath kettle at 40 ℃.

The method according to any one of the embodiments of the first aspect of the present invention, wherein in step (1), the cryopreserved cord blood hematopoietic stem cells are subjected to resuscitation treatment as follows: taking out the frozen cord blood hematopoietic stem cells from the liquid nitrogen tank, putting the cord blood hematopoietic stem cells into a water bath kettle at 40 ℃, and completing the unfreezing process within 1 minute. Thawing at this rate maximizes cell viability.

The method according to any one of the embodiments of the first aspect of the present invention, wherein the cell frozen stock solution added to the cord blood hematopoietic stem cells obtained by the separation comprises: about 65 parts DMEM-F12, about 10 parts dimethyl sulfoxide, about 15 parts human serum albumin.

The method according to any embodiment of the first aspect of the invention, wherein the PBS buffer is formulated with sodium and/or potassium salts of phosphoric acid, and has a pH of 5.0-8.0, preferably a pH of 5.5-7.6, preferably a pH of 6.0-7.5. In one embodiment, the phosphate concentration in the PBS buffer is between 0.01 and 0.5M, preferably between 0.02 and 0.1M. In the experiments underlying the present invention, the PBS buffer used was a sodium phosphate salt, with a phosphate concentration of 0.025M and a pH of 7.2. It should be noted that the present inventors found that the concentration and pH of the PBS buffer within the above-mentioned ranges do not greatly affect the effect of the method of the present invention.

The method according to any one of the embodiments of the first aspect of the present invention, wherein the hematopoietic stem cell culture system further comprises 0.02 to 0.05. mu. mol/L disodium adipate and 0.05 to 0.15% (w/v) maltose. It has been surprisingly found that the addition of these two agents to a hematopoietic stem cell culture system can greatly increase CD34⁺Fold expansion of cells, and CD34⁺Cellular performance is not affected.

Further, the second aspect of the present invention provides a cell preparation comprising CD34 prepared according to the method of any one of the embodiments of the first aspect of the present invention⁺A cell and a pharmaceutically acceptable carrier.

Alternatively, and further, the second aspect of the invention provides a cell preparation or also referred to as a cell therapy composition comprising CD34⁺A cell and a pharmaceutically acceptable carrier, the cell preparation being prepared by a method comprising the steps of:

(6) day 4 of culture, CD34 was performed⁺Cell counts, when reaching 4-6 x10 ^5 cells according to 1 x10 ^5 CD34⁺Performing plate separation treatment when cells/holes are processed;

(8) CD34 using a flow cytometer⁺Count and evaluate CD34⁺The effect of cell expansion;

(9) harvesting CD34⁺The cells are mixed with a pharmaceutically acceptable carrier to make a cell preparation.

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein in step (1), the cord blood hematopoietic stem cells are isolated by using an AXP full-automatic isolation system.

The cell preparation according to any of the second aspect of the present invention, wherein in the step (1), the cord blood hematopoietic stem cells are isolated by an AXP full-automatic separation system^TMPlatform。

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein in step (1), the erythrocyte removal rate of the AXP-treated cord blood sample is usually 80% or more.

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein said PBS buffer is a sodium phosphate salt buffer, wherein the phosphate concentration is 0.025M, ph 7.2. The sodium phosphate salt buffer may be formulated using sodium dihydrogen phosphate and/or disodium hydrogen phosphate, optionally in combination with phosphoric acid or sodium hydroxide to adjust the pH, such formulation methods being well known to those skilled in the art.

The cell preparation according to any embodiment of the second aspect of the present invention, wherein in step (3), the centrifugation conditions are: centrifuging at 1800rpm for 20min, increasing speed to 1, and decreasing speed to 0.

The cell preparation according to any embodiment of the second aspect of the present invention, wherein said flow cytometer is a FC500 type flow cytometer or other type of flow cytometer commonly used in the art.

The cell preparation according to any embodiment of the second aspect of the invention, wherein said hematopoietic stem cell culture system consists of: 25-75 μ g/ml of Human low density lipoprotein (Human LDL), 5-15 ng/ml of Erythropoietin (EPO), 500-1500 IU/ml of interleukin 3(IL-3), 25-75 ng/ml of Stem Cell Factor (SCF) and a proper amount of animal component-free culture medium (StemBan-ACF) are added to the whole volume of the preparation solution.

The cell preparation according to any embodiment of the second aspect of the invention, wherein said hematopoietic stem cell culture system consists of: human low density lipoprotein (Human LDL)50 μ g/ml, Erythropoietin (EPO)10ng/ml, interleukin 3(IL-3)1000IU/ml, Stem Cell Factor (SCF)50ng/ml, animal component free medium (StemBan-ACF) were added in appropriate amounts to the full volume of the formulation.

The cell preparation according to any embodiment of the second aspect of the invention, wherein said parameter for assessing the effect of amplification may be, for example, fold expansion, colony forming units (which may be, for example, CFU-E, BFU-E, CFU-GM, CFU-GEMM, etc.).

The cell preparation according to any embodiment of the second aspect of the present invention, wherein in step (1), the cord blood hematopoietic stem cells obtained by separation are optionally further subjected to cryopreservation and resuscitation treatment, and then used for the treatment of step (2).

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein in step (1), the cord blood hematopoietic stem cells obtained by isolation are subjected to the following cryopreservation treatment: adding cell frozen stock solution into cord blood hematopoietic stem cells obtained by separation, cooling, and storing in a gaseous liquid nitrogen storage tank at-196 ℃.

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein in the step (1), the cryopreserved cord blood hematopoietic stem cells are subjected to a resuscitation treatment as follows: taking out the frozen cord blood hematopoietic stem cells from the liquid nitrogen tank, and unfreezing the cord blood hematopoietic stem cells in a water bath kettle at 40 ℃.

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein in the step (1), the cryopreserved cord blood hematopoietic stem cells are subjected to a resuscitation treatment as follows: taking out the frozen cord blood hematopoietic stem cells from the liquid nitrogen tank, putting the cord blood hematopoietic stem cells into a water bath kettle at 40 ℃, and completing the unfreezing process within 1 minute. Thawing at this rate maximizes cell viability.

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein the cell cryopreserved added to the cord blood hematopoietic stem cells obtained by the separation comprises: about 65 parts DMEM-F12, about 10 parts dimethyl sulfoxide, about 15 parts human serum albumin.

The cell preparation according to any embodiment of the second aspect of the invention, wherein the PBS buffer is formulated with sodium and/or potassium salts of phosphoric acid, and has a pH of 5.0-8.0, preferably a pH of 5.5-7.6, preferably a pH of 6.0-7.5. In one embodiment, the phosphate concentration in the PBS buffer is between 0.01 and 0.5M, preferably between 0.02 and 0.1M. In the experiments underlying the present invention, the PBS buffer used was a sodium phosphate salt, with a phosphate concentration of 0.025M and a pH of 7.2. It should be noted that the present inventors found that the concentration and pH of the PBS buffer within the above-mentioned ranges do not greatly affect the effect of the method of the present invention.

The cell preparation according to any one of the embodiments of the second aspect of the present invention, wherein the hematopoietic stem cell culture system further comprises 0.02 to 0.05. mu. mol/L disodium adipate and 0.05 to 0.15% (w/v) maltose. It has been surprisingly found that the addition of these two agents to a hematopoietic stem cell culture system can greatly increase CD34⁺Fold expansion of cells, and CD34⁺Cellular performance is not affected.

The cell preparation according to any embodiment of the second aspect of the present invention, wherein said pharmaceutically acceptable carrier is selected from the group consisting of water for injection, sodium chloride, mannitol, lactose, sucrose, and the like.

The cell preparation of the present invention may be administered parenterally according to methods conventional in the art. The administration routes of cell preparations in clinical application at present include, but are not limited to, local injection transplantation and cyclic injection transplantation. The cell preparation according to the invention can be prepared in any form suitable for administration. For example, prepared to be suitable for incorporation of CD34 by micropump⁺A form in which a cell preparation of cells is pumped into the target area; or prepared to be suitable for containing CD34 through a puncture needle⁺A cell preparation of cells infused into the target area. The selection of an appropriate pharmaceutically acceptable carrier can be determined by one skilled in the art depending on the implantation mode and the purpose of treatment. In some embodiments, the pharmaceutically acceptable carrier is physiological saline.

Alternatively, in a second aspect, the invention provides a cell therapy compositionWhich comprises the following steps: CD34⁺Cells, sodium chloride, water for injection.

The cell therapy composition according to the second aspect of the present invention, said CD34⁺The cells are cord blood hematopoietic stem cell source CD34⁺A cell; for example, the compound is produced by the method described in the present invention, for example, the method described in the first aspect or the second aspect of the present invention.

The cell therapy composition according to the second aspect of the present invention, comprising: CD34⁺Cells, sodium chloride, water for injection.

The cell therapy composition according to the second aspect of the present invention, wherein CD34⁺The density of cells was 1X 10⁶one/mL to 5X 10⁶one/mL, e.g. 2X 10⁶one/mL to 4X 10⁶one/mL, e.g. 3X 10⁶one/mL.

The cell therapy composition according to the second aspect of the present invention, wherein the mass volume percentage of sodium chloride is 0.8% to 1.0% or 0.9%.

The cell therapy composition according to the second aspect of the present invention, wherein the amount of water for injection is added to the CD34⁺The amount of cells that reach their specified density.

The cell therapy composition according to the second aspect of the present invention, comprising: 1X 10⁶one/mL to 5X 10⁶CD34 of one/mL⁺Cells, 0.8-1.0% of sodium chloride and water for injection.

The cell therapy composition according to the second aspect of the present invention, comprising: 2X 10⁶one/mL to 4X 10⁶CD34 of one/mL⁺Cells, 0.8-1.0% of sodium chloride and water for injection.

The cell therapy composition according to the second aspect of the present invention, comprising: 3X 10⁶CD34 of one/mL⁺Cells, 0.9% sodium chloride, and water for injection.

The cell therapy composition according to the second aspect of the present invention, further comprising magnesium chloride.

The cell therapy composition according to the second aspect of the present invention, wherein the mass volume percentage of the magnesium chloride is 0.05% to 0.1%.

In the present invention, unless otherwise specified, all references to% refer to mass volume percent.

The cell therapy composition according to the second aspect of the present invention, wherein the mass volume percentage of the magnesium chloride is 0.08%.

The cell therapy composition according to the second aspect of the present invention, further comprising calcium sodium edetate.

The cell therapy composition according to the second aspect of the present invention, wherein the mass volume percentage of the calcium sodium edetate is 0.06% -0.08%.

The cell therapy composition according to the second aspect of the present invention, wherein the mass volume percentage of the calcium sodium ethylenediaminetetraacetate is 0.07%.

The cell therapy composition according to the second aspect of the present invention, wherein:

(4) which comprises the following steps: CD34⁺Cells 4X 10⁶Sodium chloride 0.85%, magnesium chloride 0.07%, calcium disodium edetate 0.075%, and water for injection.

In the cell therapy composition of the present invention, the survival rate is greatly reduced due to insufficient nutrition if the density of the stem cells is too high, the survival rate is not maintained due to too low density of the stem cells, and the amount of the preparation required is increased due to too low density of the stem cells. The invention proves that the density of the stem cells is 1 multiplied by 10 through experiments⁶one/mL-5X 10⁶The survival rate of stem cells is highest when the cells are cultured per mL.

The compositions of the present invention are aqueous suspensions comprising sodium chloride at a concentration substantially equivalent to physiological saline. The normal saline is sodium chloride solution with osmotic pressure equal to that of animal or human plasma, which is commonly used in physiological experiments or clinic. Therefore, the target cells in the cell therapeutic composition of the present invention are substantially dispersed in physiological saline, i.e., a sodium chloride solution with a mass volume percentage of 0.9%, and the osmotic pressure of the cells is consistent with that of human tissues, and the target cells are not damaged by using the physiological saline as a solvent.

The molecular formula of the calcium sodium ethylene diamine tetracetate used in the invention is C10H12N2O8CaNa2.2H2O, and the calcium sodium ethylene diamine tetracetate is white crystal particles or white to offwhite powder, and the pH value of a 1% aqueous solution of the calcium sodium ethylene diamine tetracetate is 6.0-7.0. Calcium sodium ethylene diamine tetracetate is odorless, slightly salty, slightly hygroscopic, stable in air, easily soluble in water and hardly soluble in ethanol, is usually used as a chelating agent, a preservative and an antioxidant, has the effect of stabilizing the quality of a product by combining free metals, and is usually used for eliminating the inhibition of enzyme catalytic reaction caused by trace heavy metals.

The magnesium chloride used in the present invention may be an anhydride or a hydrate, and may be, for example, a hexahydrate. In the present invention, the amount of magnesium chloride is calculated as an anhydride regardless of the form of magnesium chloride used, unless otherwise specified.

The cell therapy composition according to the second aspect of the present invention is prepared according to a method comprising the steps of:

dissolving sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium edetate) in water, optionally sterilizing the solution to obtain matrix of the preparation;

mixing the pre-made CD34⁺Suspending the cells in the matrix, and packaging.

The cell therapy composition according to the second aspect of the present invention is prepared under aseptic conditions.

According to a second aspect of the inventionThe cell therapy composition is prepared by mixing with CD34⁺The temperature of the matrix before cell mixing was below 25 ℃.

The cytotherapeutic composition according to the second aspect of the present invention is prepared by contacting the substrate with CD34 at a temperature of less than 25 ℃⁺The cells are mixed.

The CD34 provided by the invention⁺The cell therapy composition is simple and mild in preparation method, and does not damage the activity of stem cells, thereby improving CD34⁺Survival of stem cells in cell preparations.

The cell therapy composition according to the second aspect of the present invention, wherein the dispensing is dispensing the formulated cell therapy composition into pre-filled syringes, particularly into single-use pre-filled syringes.

In the cell therapy composition according to the second aspect of the present invention, the cylinder of the prefilled syringe is made of a polymer (e.g., polypropylene) and the piston is made of rubber, and in the embodiment of the present invention, as not particularly illustrated, the cylinder of the prefilled syringe is made of a polymer (e.g., polypropylene) and the piston is made of rubber.

Prefilled syringes were first introduced during world war ii in order to meet the field sterile medical needs of field hospitals. The re-forced marketing of prefilled syringes was in the early 50 s of the last century when Becton Dickinson provided glass prefilled syringes for the polio vaccine program of Jonas Salks, Rooibos. Thereafter, prefilled syringes continue to be used, mostly in the field of insulin and human growth hormone administration. However, the real prevalence of pre-filled syringes has been in the past 5 years, almost becoming a product that must be provided by the injection supplier. While most of the innovative liquid drugs, if appropriate, will be marketed in prefilled syringes. Pre-filled syringes are especially appealing due to the advantages of the product itself, especially ease of use. The pharmaceutical market is changing, biotechnological therapies and the number of drug candidates that can be administered only by injection route is increasing, and they are involved in a very wide range of therapeutic fields, such as multiple sclerosis, infertility, osteoporosis, hepatitis, rheumatoid arthritis, cancer, anemia and hemophilia. Some biotech drugs require frequent administration by the patient himself, who benefits most deeply from the convenience of a prefilled syringe, since the prefilled syringe saves some handling steps and allows a faster and easier use. The need of the patient is a real motivation to advance the development of prefilled syringes. The metering of a drug from a vial into a syringe is a time consuming task and is prone to error by persons lacking adequate training. In addition, patients with certain diseases such as rheumatoid arthritis often have difficulty, if not even being able to hold a stable vial and measure out the correct dose. Pharmaceutical manufacturers have changed some drugs from lyophilized to liquid dosage forms to fill prefilled syringes, for example Berlex's therapeutic multiple sclerosis drug Betaseron, norkino's human auxin Norditropin, and gene tack's human auxin Nutropin have all changed from lyophilized to liquid dosage forms to fill prefilled syringes for sale. Syringe component manufacturers are speeding up to meet the ever increasing demand for ready-to-use components. The ready-to-use plunger from Stelmi, France and the Hypak SCF prefilled syringe from Becton Dickinson, make filling on-site without the need for cleaning, depyrogenation and sterilization operations. The ready-to-use element can be directly used after being cleaned, sterilized by ethylene oxide or gamma rays and verified. Another advantage of prefilled syringes is that the amount of product overfill can be significantly reduced. By using the prefilled syringe, 10%, 15%, and sometimes even 20% of the drug substance can be saved. Some manufacturers that change vials to prefilled syringes also reduce the bulk drug yield because the new dosage form no longer requires as much bulk drug. One study by Becton Dickinson showed that the dose in a prefilled syringe can be 23% higher than a vial because there is less drug loss during transfer from vial to syringe.

Further, the third aspect of the present invention provides a use of the cell therapy composition or the cell preparation according to any one of the embodiments of the second aspect of the present invention for preparing a medicament for alleviating or improving vascular disorders.

Alternatively, or in addition, to the first and second embodiments,in a third aspect of the invention, CD34 is provided⁺Use of cells in the manufacture of a medicament for alleviating or ameliorating a vascular disorder, the medicament being prepared by a method comprising the steps of:

(6) day 4 of culture, CD34 was performed⁺Cell counts, when reaching 4-6 x10 ^5 cells according to 1 x10 ^5 CD34⁺Cell/well timeCarrying out plate separation treatment;

(8) CD34 using a flow cytometer⁺Count and evaluate CD34⁺The effect of cell expansion;

(9) harvesting CD34⁺Mixing the cells with pharmaceutically acceptable carrier, and making into medicine.

The use according to any of the embodiments of the third aspect of the present invention, wherein in step (1), the cord blood hematopoietic stem cells are isolated by using an AXP full-automatic isolation system.

The use according to any of the embodiments of the third aspect of the present invention, wherein in the step (1), the cord blood hematopoietic stem cells are isolated by using an AXP full-automatic separation system^TMPlatform。

The use according to any of the embodiments of the third aspect of the present invention, wherein in step (1), the erythrocyte removal rate of the AXP-treated cord blood sample is usually above 80%.

The use according to any one of the embodiments of the third aspect of the present invention, wherein the PBS buffer is a sodium phosphate salt buffer, wherein the phosphate concentration is 0.025M, ph 7.2. The sodium phosphate salt buffer may be formulated using sodium dihydrogen phosphate and/or disodium hydrogen phosphate, optionally in combination with phosphoric acid or sodium hydroxide to adjust the pH, such formulation methods being well known to those skilled in the art.

The use according to any one of the embodiments of the third aspect of the present invention, wherein in step (3), the conditions of the centrifugation treatment are: centrifuging at 1800rpm for 20min, increasing speed to 1, and decreasing speed to 0.

The use according to any of the embodiments of the third aspect of the present invention, wherein the flow cytometer is a FC500 type flow cytometer or other types of flow cytometer commonly used in the art.

The use according to any of the embodiments of the third aspect of the invention, wherein the composition of the hematopoietic stem cell culture system is: 25-75 μ g/ml of Human low density lipoprotein (Human LDL), 5-15 ng/ml of Erythropoietin (EPO), 500-1500 IU/ml of interleukin 3(IL-3), 25-75 ng/ml of Stem Cell Factor (SCF) and a proper amount of animal component-free culture medium (StemBan-ACF) are added to the whole volume of the preparation solution.

The use according to any of the embodiments of the third aspect of the invention, wherein the composition of the hematopoietic stem cell culture system is: human low density lipoprotein (Human LDL)50 μ g/ml, Erythropoietin (EPO)10ng/ml, interleukin 3(IL-3)1000IU/ml, Stem Cell Factor (SCF)50ng/ml, animal component free medium (StemBan-ACF) were added in appropriate amounts to the full volume of the formulation.

The use according to any of the embodiments of the third aspect of the present invention, wherein the evaluation parameter of the amplification effect may be, for example, amplification fold, colony forming unit (which may be, for example, CFU-E, BFU-E, CFU-GM, CFU-GEMM, etc.).

The use according to any of the embodiments of the third aspect of the present invention, wherein in the step (1), the cord blood hematopoietic stem cells obtained by separation are optionally subjected to cryopreservation and resuscitation treatment, and then are used for the treatment of the step (2).

The use according to any of the embodiments of the third aspect of the present invention, wherein in the step (1), the cord blood hematopoietic stem cells obtained by isolation are subjected to the following cryopreservation treatment: adding cell frozen stock solution into cord blood hematopoietic stem cells obtained by separation, cooling, and storing in a gaseous liquid nitrogen storage tank at-196 ℃.

The use according to any of the embodiments of the third aspect of the present invention, wherein in step (1), the cryopreserved cord blood hematopoietic stem cells are subjected to resuscitation treatment as follows: taking out the frozen cord blood hematopoietic stem cells from the liquid nitrogen tank, and unfreezing the cord blood hematopoietic stem cells in a water bath kettle at 40 ℃.

The use according to any of the embodiments of the third aspect of the present invention, wherein in step (1), the cryopreserved cord blood hematopoietic stem cells are subjected to resuscitation treatment as follows: taking out the frozen cord blood hematopoietic stem cells from the liquid nitrogen tank, putting the cord blood hematopoietic stem cells into a water bath kettle at 40 ℃, and completing the unfreezing process within 1 minute. Thawing at this rate maximizes cell viability.

The use according to any of the embodiments of the third aspect of the present invention, wherein the cell frozen stock solution added to the cord blood hematopoietic stem cells obtained by the separation comprises: about 65 parts DMEM-F12, about 10 parts dimethyl sulfoxide, about 15 parts human serum albumin.

The use according to any of the embodiments of the third aspect of the present invention, wherein the PBS buffer is formulated with sodium and/or potassium salts of phosphoric acid, and has a pH of 5.0-8.0, preferably a pH of 5.5-7.6, preferably a pH of 6.0-7.5. In one embodiment, the phosphate concentration in the PBS buffer is between 0.01 and 0.5M, preferably between 0.02 and 0.1M. In the experiments underlying the present invention, the PBS buffer used was a sodium phosphate salt, with a phosphate concentration of 0.025M and a pH of 7.2. It should be noted that the present inventors found that the concentration and pH of the PBS buffer within the above-mentioned ranges do not greatly affect the effect of the method of the present invention.

The use according to any one of the embodiments of the third aspect of the present invention, wherein the hematopoietic stem cell culture system further comprises 0.02 to 0.05. mu. mol/L disodium adipate and 0.05 to 0.15% (w/v) maltose. It has been surprisingly found that the addition of these two agents to a hematopoietic stem cell culture system can greatly increase CD34⁺Fold expansion of cells, and CD34⁺Cellular performance is not affected.

The use according to any of the embodiments of the third aspect of the present invention, wherein said pharmaceutically acceptable carrier is selected from the group consisting of water for injection, sodium chloride, mannitol, lactose, sucrose, and the like.

The use according to any of the embodiments of the third aspect of the invention, wherein said pharmaceutically acceptable carrier comprises: water for injection, sodium chloride, magnesium chloride and ethylene diamine tetraacetic acid calcium sodium.

The use according to any embodiment of the third aspect of the invention, wherein the medicament of step (9) is according to any embodiment of the second aspect of the invention.

The use according to any of the embodiments of the third aspect of the invention, wherein the vascular disorder is limb arterial stenotic occlusion or Peripheral Arterial Disorder (PAD) caused by diabetes; preferably arterial stenosis of the limb or arterial lesions of the lower limb caused by diabetes.

Further, the fourth aspect of the present invention provides a method for preparing a cell therapy composition or a cell preparation according to any one of the embodiments of the second aspect of the present invention, which comprises the steps of:

dissolving sodium chloride (and optionally magnesium chloride and/or optionally calcium sodium edetate) in water, optionally sterilizing the solution to obtain matrix of the preparation;

mixing the pre-made CD34⁺Suspending the cells in the matrix, and packaging.

According to the method of the fourth aspect of the present invention, the preparation process is carried out under aseptic conditions.

The method according to the fourth aspect of the present invention, wherein the CD34 is added during the preparation process⁺The temperature of the matrix before cell mixing was below 25 ℃.

According to the method of the fourth aspect of the invention, the substrate is contacted with CD34 at a temperature of less than 25 ℃⁺The cells are mixed.

The method according to the fourth aspect of the present invention, wherein the dispensing is dispensing the formulated cell therapy composition into pre-filled syringes, particularly into single-use pre-filled syringes.

According to the method of the fourth aspect of the present invention, the material of the cylinder of the prefilled syringe is a polymer (e.g. polypropylene) and the material of the piston is rubber, and in the embodiment of the present invention, as not specifically described, the material of the cylinder of the prefilled syringe is a polymer (e.g. polypropylene) and the material of the piston is rubber.

According to any aspect of the present invention, wherein the cell therapy composition further comprises magnesium chloride and/or optionally calcium sodium edetate in specified amounts, it has been surprisingly found that the combination of magnesium chloride and/or calcium sodium edetate provides a composition that exhibits superior cell recovery performance during cell recovery, and that the viability of cells undergoing recovery and the stability of cells after recovery is significantly higher than other solutions without magnesium chloride and calcium sodium edetate.

According to any aspect of the present invention, wherein said CD34⁺Cells, unless otherwise specified, are prepared according to the methods described in the section of the embodiments of the present invention, for example, CD34 prepared in step (9) of examples 4 to 6 of the present invention⁺A cell.

In the above-described steps of the preparation method of the present invention, although the specific steps described therein are distinguished in some detail or in language description from the steps described in the preparation examples of the detailed embodiments below, those skilled in the art can fully summarize the above-described method steps in light of the detailed disclosure throughout the present disclosure.

Any embodiment of any aspect of the invention may be combined with other embodiments, as long as they do not contradict. Furthermore, in any embodiment of any aspect of the invention, any feature may be applicable to that feature in other embodiments, so long as they do not contradict. The invention is further described below.

All documents cited herein are incorporated by reference in their entirety and to the extent such documents do not conform to the meaning of the present invention, the present invention shall control. Further, the various terms and phrases used herein have the ordinary meaning as is known to those skilled in the art, and even though such terms and phrases are intended to be described or explained in greater detail herein, reference is made to the term and phrase as being inconsistent with the known meaning and meaning as is accorded to such meaning throughout this disclosure.

The cell therapy composition provided by the invention has excellent properties.

In the present invention, the term "PBS buffer" or "PBS" refers to a phosphate buffer. The general formulation and formulation of the PBSs used in the context of the present invention and their general properties such as pH or pH range are well known to the person skilled in the art.

In the present invention, the term "umbilical cord" refers to the umbilical cord of a newborn, and particularly to the umbilical cord within 4 hours of birth.

In the present invention, the term "cord blood" refers to the cord blood of newborn, particularly to the cord blood within 4 hours after birth.

The cd34 molecule is a highly glycosylated type i transmembrane glycoprotein, selectively expressed on the surface of human and other mammalian hematopoietic stem/progenitor cells, and gradually diminishes to disappear as the cells mature. The results of more and more researches show that the cd34 molecule plays an important role in mediating the intercellular adhesion, can participate in the transportation and colonization of hematopoietic stem cells, and participate in inflammatory reaction and the homing of lymphocytes.

The cd34 molecule was discovered by civin, an american scientist, in 1984, to belong to the cadherin family, whose structure includes an extracellular domain, a transmembrane domain, and a cytoplasmic domain 3 portion [ anlngxing, anxu. cd34 molecule and its monoclonal antibody application [ j ]. china journal of blood transfusion, 2003, 16 (5): 350-354]. As an adhesion molecule, cd34 molecule is selectively expressed on the surface of human and other mammalian hematopoietic stem/progenitor cells (hsc/hpc) and gradually diminishes to disappear as the cells mature. Intercellular adhesion is a complex process involving multiple mechanisms and factors, and plays a crucial role in the evolution process, cell regulation, tissue physiology, and disease development of multicellular organisms [ leckbandd, prakasama. mechanism and dynamics of cadherin addition [ j ]. annu rev biomedingg, 2006 (8): 259-287]. Adhesion molecules act in a receptor-ligand binding mode, participate in recognition, activation and signal transduction of cells, and proliferation and differentiation, extension and movement of cells, and are the molecular basis of a series of important physiological and pathological processes such as immune response, inflammation generation, blood coagulation, tumor metastasis, wound healing and the like [ cheynet peak. medical immunology [ m ] 3 edition. Beijing: national health press, 2000: 66-78; zhu c, baig, wangn. cellmecanics: mechanical response, cellaldhese, and molecular evolution [ j ]. annu rev biomod eng, 2000 (2): 189-226]. During hematopoietic stem cell transplantation, cd34 molecule plays a role in transporting hematopoietic stem cells (hscs), and under the action of mobilizing agent, hscs are promoted to migrate away from bone marrow and enter peripheral blood to complete the mobilization process [ wufeng jianyu, etc.. g-csf influences the expression of cd34+ cell adhesion molecules in peripheral blood of donors [ j ]. china journal of blood transfusion, 2007, 20 (2): 105-107], and mediates binding to the bone marrow microenvironment to enhance hsc engraftment [ yin t, lilh. the stem cell niche bone [ j ]. clin invent, 2006, 116 (3): 652-662].

The cd34 molecule is a highly glycosylated type i transmembrane glycoprotein, selectively expressed on the surface of human and other mammalian hematopoietic stem/progenitor cells, and gradually diminishes to disappear as the cells mature. The cd34 molecule has long been used with its unique superiority as a standard for screening hsc/hpc [ platzbecker u, ehningerg, bomhauserm, et. allogenic transformation of cd34+ selected biochemical cells-clinical schemes and currentgalleries [ j ]. leuk lymphoma, 2004, 45 (3): 447-453]. The cd34 molecule is a member of cadherin family, is a monomeric surface protein with a relative molecular weight of 115000-120000, and the main frame of the carbon chain generally has a relative molecular weight of only 40000 and has no sequence homology with other known proteins [ gurudua u, vimalk, yogeshk, et. hematopoeit cell antigen cd 34: roll in addition halogenation [ j ]. stem cells and dev, 2006, 15 (3): 305-313]. The cd34 molecular structure includes extracellular, transmembrane and cytoplasmic domain 3 portions. The extracellular region is the main part of the interaction between the cd34 molecule and other molecules, and is approximately composed of 278 amino acid residues, the n-terminal part is very glycosylated, 9 n-chain sugar connecting sites and a large number of chain sugar connecting sites are provided, the content of serine and threonine in 145 terminal amino acid residues is more than 35 percent, the extracellular region is a sialylation site concentration region, and abundant chain sugar can protect the cd34 molecule from being hydrolyzed by certain proteases so as to maintain the stability of the structure and provide a specific recognition site. The transmembrane region contains 22 hydrophobic amino acid residues, is a 1-transmembrane helical structure and has the characteristics of an i-type transmembrane protein. The cytoplasmic domain consists of 73 hydrophobic amino acid residues, and the ligand is recognized by regulatory protein crk-l and also plays a role in inducing cell aggregation [ gangenahaligu, singh vk, verma yk, et al. this-dimensional structural prediction of the interaction of cd34with the 3 domain of crk-l [ j ]. stemcells dev, 2005, 14 (5): 470-477].

The cd34 molecule is involved in the trafficking of HSPC (hematopoietic stem progenitor cells). lyn et al [ lyn h, gillianm, karing, et. the term cell antigen cd34 functions as a regulator of physiotic cell membrane disease [ j ]. proc nat acad sci usa, 1995, 92 (26): 12240-12244] 1 st indication that the cd34 molecule on hsc directly participates in cell adhesion, they found that the mouse thymocyte of cd34+ can specifically bind with the mesenchymal cell of human origin in the model study of cd34+ transgenic mice, while the mouse thymocyte of the same hu-cd34+ cannot bind with the mesenchymal cell of mouse origin, thus indicating that the cd34 molecule can play the role of mediating the binding of the two. In experiments, they unexpectedly found that monoclonal antibodies (mabs) against cd34 reduced the binding specificity but enhanced the adhesion force, mainly due to binding of murine thymocytes of hu-cd34+ to monoclonal antibodies against cd34, which up-regulated the binding of cd34 molecules to the mesenchymal layers of the bone marrow. These indicate that intermolecular signal transduction between the extracellular domain of hu-cd34 and its ligand can induce the expression of cell surface adhesion molecules or maintain the functional state of high intercellular affinity. Accordingly, it was thought by the scholars that in hsc/hpc homing, cd34 molecules on the surface of hsc/hpc first initiated initial adhesion with l-selectin of endothelial cells and bone marrow stroma; then, the molecules involved in adhesion are increased and enhanced, and the molecules comprise integrin molecules (such as vla-4) of cd34 cells and ligands thereof positioned on bone marrow stroma (such as vascular cell adhesion molecule-1). The hsc/hpc then terminates the cycle, traverses the endothelial cell layer, localizes to the bone marrow extra-vascular matrix, proliferates and differentiates, and completes the homing process. cd 34-mediated adhesion signaling is accomplished by tyrosine-protein kinase (tpk), a tpk-specific inhibitor, herbimycin a, that can block cellular adhesion [ major o, st-ckl j, pickl wf, et al. 1226-1234]. In the presence of cd34, hsc persistently expresses g protein-coupled receptors (gpcrs): cxcr4, cyslt1, s1p, s1p1 etc. [ xue x, caiz, seitzg, ethyl. differential effects of g protein coupled receptors on biochemical promoter cells growing down and on the same signaling capsules [ j ]. an n y access sci, 2007, 1106 (1): 180-189], causing chemotaxis and adhesion of cells and resulting migration and aggregation of hscs.

It is now basically believed that cd34 molecule mainly acts with l, p selectins in the hsc transport process, and indirect experimental results demonstrate that under abnormal myeloproliferative conditions [ buccisano f, maurillol, tambouria, ethyl. evaluationof the pathological recurrence of l-selectin and icam1 expresson myo-alcoholic syndromes [ j ]. haematol, 2008, 80 (2): 107- "114") or during hematopoietic recovery [ wo juciechowski jc, narasipeusd, charlesn, et al. captureand expression of cd34-positive haematatopoetic stem and promoter cells from blood circulation p-selection in an implantable device [ j ]. haematol, 2008, 140 (6): 673-. In addition, the degree of marrow infiltration and hematopoietic recovery can be predicted by detecting the expression level of selectins or other adhesion molecules in the marrow stroma.

The cd34 molecule is involved in inflammatory responses. Inflammation occurs mainly due to the interaction of adhesion molecules, which causes the adhesion of leukocytes and the migration of leukocytes to inflammatory sites through vascular endothelial cells. In the process, on one hand, the cd34 molecule, e-selectin and p-selectin act together, are connected with a leukocyte surface receptor through a side chain, mediate the aggregation of leukocytes, start inflammatory reaction, and simultaneously cooperate with the action of chemokines to enhance the inflammatory reaction, and researches show that the cd34 molecule has abnormal expression in inflammation, especially chronic inflammatory diseases such as pneumonia, asthma and chronic otitis media; on the other hand, the activated vascular endothelial cells migrate under the combined action of adhesion molecules and chemokines, which is beneficial to endothelial repair and vascular reconstruction.

The cd34 molecule is involved in lymphocyte homing in cooperation with selectins. The cd34 molecule is a phosphoprotein that is phosphorylated by protein kinase c (pkc) and upregulates surface expression by phosphorylating residues 356 and 363 of the cd34 precursor protein. Studies have shown that the sulfated glycoform cd34 on the surface of the high endothelial vein (hev) interacts with l-selectin. suzawa et al, through studies on colonic mucosa of ulcerative colitis, demonstrated that the interaction between l-selectin and peripheral lymphokine (pnad) plays an important role in lymphocyte recirculation, and cd34 molecule is involved in lymphocyte homing as peripheral lymph node neurotransmitter and in primary lymphocyte recirculation, thereby supplementing t and b lymphocytes of peripheral lymph nodes.

In the clinical application of the cd34 molecule mediated adhesion in the field of hematopoietic stem cell transplantation, the cd34 molecule is widely applied to the clinic as a marker for screening and counting hematopoietic stem cells in the hematopoietic stem cell transplantation treatment process. During peripheral blood stem cell mobilization before transplantation, the expression of related adhesion molecules is reduced under the influence of the mobilizing agent, so that the hematopoietic stem/progenitor cells easily pass through the marrow blood barrier and enter peripheral blood. In the process, the expression levels of the cd34 molecule and the ligand cd62l thereof are not obviously reduced, so that the steady state of the bone marrow stem cell pool is maintained; in the process of transplanting the hematopoietic stem cells after transplantation, the cd34 molecule improves the expression of related cytokines in the adhesion process, enhances the aggregation and combination of the cd34 molecule and bone marrow stromal cell surface molecules, enhances the colonization of the hematopoietic stem cells, and promotes the transplantation of the hematopoietic stem cells, the recovery of the hematopoietic function and the reconstruction of the immunologic function.

With the extensive and intensive research on the mechanism of cd 34-mediated cell-cell adhesion, many other cell types, such as some leukemia cells, solid tumor cells, vascular endothelial cells, and fibroblasts, have been shown to express cd34 molecules in addition to hematopoietic stem/progenitor cells. The mechanism by which cd34 molecules mediate adhesion has not been fully elucidated so far, and the mechanism by which ligands/receptors specific for cd34 molecules and interactions of intracellular protein molecules activate adhesion molecules, particularly the selectin family, remains to be further elucidated. Because the intercellular adhesion is closely involved in a series of important physiological and pathological processes such as in vivo immune response, inflammation generation, blood coagulation, tumor metastasis, wound healing and the like, the CD34 molecule has definite action mechanism and further application, has important significance for clinically diagnosing and treating hematopathy, treating solid tumor and identifying the benign and malignant tumor and origin, and has wide application prospect in the fields of organ transplantation, hematopoietic stem cell transplantation and the like.

Mesenchymal Stem Cells (MSCs), such as human mesenchymal stem cells, were first isolated from bone marrow and a class of tissue stem cells derived from the mesoderm, which have the potential for multipotent differentiation and the ability to self-renew, have the ability to differentiate into various adult cells, such as osteoblasts, chondrocytes, adipocytes, endothelial cells, nerve cells, muscle cells, hepatocytes, etc., under specific conditions in vivo and in vitro (Cap AI. mesenchyme stem cells. Jthop Res.1991,9:641-650.Pittenger MF, Mackay AM, Beck, et al. multilineagent sensory of epithelial man stem cells. science.1999; 284:143 Across 147). Recent research shows that the mesenchymal stem cells have the functions of immunoregulation and hematopoietic support, and are easy to introduce and express exogenous genes. Therefore, the mesenchymal stem cells are not only seed cells in the construction of tissue engineering bone, cartilage and cardiac muscle and important carrier cells in gene therapy, but also have wide application prospect in hematopoietic stem cell transplantation and organ transplantation because the mesenchymal stem cells promote hematopoietic reconstruction and inhibit graft-versus-host reaction. Mesenchymal stem cells have the characteristic of adherent growth in vitro, and by utilizing the characteristic, the mesenchymal stem cells are successfully separated and cultured from various tissues such as liver, kidney, pancreas, muscle, cartilage, skin, peripheral blood and the like.

At present, the reported mesenchymal stem cells are mainly derived from bone marrow and are obtained by adopting a density gradient centrifugation method. Although the separation method is simple, the donor needs to undergo a painful operation for taking marrow and the marrow is obtained during the processThe infection chance is high after the materials are neutralized and taken; because the content of MSC in human bone marrow is very rare, every 10⁵～10⁶Only about 1 of the mononuclear cells are present, and the number, proliferation and differentiation capacity of mesenchymal stem cells in the bone marrow are remarkably reduced with the increase of the age, so that the research and application, particularly the clinical application of the mesenchymal stem cells are limited. The umbilical cord, which originates from the ectomesoderm of the embryo during its development, is composed of mesenchymal, vascular and trophoblasts, and contains a large amount of mesenchymal components.

Recent research shows that the umbilical cord contains abundant stem cells, and the separation and culture of the pluripotent stem cells from the umbilical cord opens up a new and abundant source for experimental research and clinical application.

The existing methods for isolating stem cells to create stem cell banks have many disadvantages, such as insufficient purity and/or low number, and thus show that these methods are not satisfactory. For example, CN 101270349a (chinese patent application No. 200810061267.6, published 24/9/2008) discloses an invention entitled "placental mesenchymal stem cell isolation and in vitro expansion culture method"; CN 101693884a (chinese patent application No. 200910117522.9, published 2010, 4 months and 14 days) entitled "a method for separating and extracting stem cells from placenta, umbilical cord or adipose tissue"; CN102146359A (chinese patent application No. 201110005964.1, published 2011/8/10) discloses an invention entitled "method for extracting original mesenchymal stem cells from placenta and serum-free expansion". These processes are to be further improved in terms of purity and/or recovery of the extract.

Mesenchymal stem cells can be isolated in large quantities from the umbilical cord and this method can be used to preserve umbilical cord mesenchymal stem cells and establish umbilical cord stem cell banks. On the basis of separating and culturing the mesenchymal stem cells, the tissue digestive enzyme is utilized to digest the umbilical cord tissue block, and the adherent culture method is combined to successfully separate a large amount of mesenchymal stem cells from the umbilical cord. The mesenchymal stem cells obtained by the method have high purity and large quantity, have the same biological characteristics as the mesenchymal stem cells of the bone marrow, and can be differentiated into osteoblasts, chondrocytes, adipocytes, endothelial cells, nerve cells and the like. As the stem cells in the umbilical cord are more immature than adult stem cells, rich in content and wide in clinical application prospect, the mesenchymal stem cells are cryopreserved like cord blood by using a conventional cell cryopreservation method, an umbilical cord stem cell bank is established, and a foundation is laid for the further research and clinical treatment of the stem cells.

Because the cord blood contains abundant hematopoietic stem cells, people establish a cord blood bank to store the cord blood hematopoietic stem cells which are an important biological resource, and a treatment means is provided for various blood system diseases and immune system diseases. Similarly, umbilical cord mesenchymal stem cells are used as a more important stem cell resource, and are frozen in deep low-temperature liquid nitrogen at the temperature of 196 ℃ below zero by using a conventional cell freezing method for long-term storage, an umbilical cord stem cell bank is established, and seeds are stored for the future stem cell treatment.

The invention adopts the AXP full-automatic separation system such as the AXP Auto Xpress to the umbilical cord blood^TMThe Platform full-automatic stem cell separation system is used for separation. Such AXP full-automatic separation system has very excellent cell separation performance: the method is characterized in that a sanitary closed centrifugal device is designed, single cord blood stem cell components are fully automatically purified from cord blood, the volume of the stem cells is reduced to a designed specified volume in the separation process, and other components in the cord blood are separated into different bags; the AXP full-automatic stem cell separation system can accurately separate 20 ml from umbilical cord blood within 40 minutes, and the recovery rate>97% of mononuclear lymphocytes, so that the number of nucleated cells is greatly increased; the AXP full-automatic stem cell separation system is provided with a computer chip, a flow path control valve and an optical sensor, automatically collects data of blood bag coding and operation in the centrifugation process by using bar codes, and meets the cGTP regulation to ensure the product quality. Compared with the traditional manual processing, the traditional manual processing time is about 2 to 4 hours, and the AXP full-automatic stem cell separation system only needs about 40 minutes; the traditional manual treatment needs to be carried out by the experience of a technician and subjective judgment, the treatment time is long, the chance of bacterial infection is increased, and the recovery rate of stem cells deviates due to the experience of the technician; when the AXP full-automatic stem cell separation system is adopted, the process from separation and collection to stem cell storageAll the processes are carried out in a sealed environment, an independent computer system records and processes data, the stability and the recovery rate are high, the processing speed is increased, the activity is increased, the sealed environment strictly avoids bacterial infection, a plurality of samples can be processed simultaneously according to the requirement, the data recording is complete, and the checking is convenient.

The invention has simple operation, convenience and practicability, and can obtain a large amount of cord blood hematopoietic stem cells, especially CD34⁺The cells have good differentiation properties and have the ability to differentiate into osteoblasts, adipocytes, chondrocytes, endothelial cells, nerve cells and other cells. The expect method is simple and easy to implement, and because the umbilical cord is the same as cord blood, the cell components are more immature, the source is wide, and the method is convenient and easy to obtain, the method has wide prospect in the clinical application of stem cells.

The cell therapy composition prepared by the method of the present invention exhibits excellent technical effects as described in the present invention.

Detailed Description

The present invention will be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be understood by those skilled in the art that various changes and modifications may be made to the invention without departing from the spirit and scope of the invention. The present invention has been described generally and/or specifically with respect to materials used in testing and testing methods. The following provides specific materials and sources thereof used in embodiments of the present invention. However, it should be understood that these are exemplary only and not intended to limit the invention, and that materials of the same or similar type, quality, nature or function as the following reagents and instruments may be used in the practice of the invention. The experimental procedures used in the following examples are all conventional procedures unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.

30页详细技术资料下载

Cell therapy compositions and methods for treating vascular disorders

相关技术

网友询问留言